Selumetinib manufacturers and suppliers in india

Selumetinib

Properties

Melting point:: >219°C (dec.)

Density: 1.69

storage temp.: -20°

solubility: Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml)

form: Beige powder.

pka: 14.20±0.10(Predicted)

color: White

Stability:: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months.

Safety Information

Symbol(GHS): GHS05,GHS07,GHS08

Signal word: Danger

Hazard statements: H317-H318-H361d-H373

Precautionary statements: P262-P280-P312

HS Code: 29349990

Use

In phase II clinical trials of radioiodine-refractory papillary thyroid carcinoma, 39 patients took daily oral doses of Selumetinib (100mg bid) for 28 days; results showed that 21 patients conditions stabilized (54%), 11 patients conditions worsened (28%), 49% patients conditions were stable for 16 weeks, 36% patients conditions were stable for 24 weeks, and survival terms did not progress to 32 weeks. Negative reactions mainly consisted of rashes (59%), diarrhea (44%), and weakness (41%). Some studies found that after treating 20 patients with thyroid cancer with Selumetinib (75mg bid) for 4 weeks, Selumetinib increased the iodine uptake and retention of patients with radioiodine-refractory papillary thyroid carcinoma. In a blind and random comparative study between a Selumetinib and Docetaxel (DOC) combination treatment group and DOC and placebo treatment group for 87 mutant NSCLSC patients, survival times were 9.4 months and 5.2 months, PFS were 5.3 months and 2.1 months, RR were 37% and 0%, thus showing dramatic differences. Selumetinibs main negative reactions include neutrophil depletion, dermatitis, and respiratory failure.